Literature DB >> 2182116

Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease.

A G Tomasselli1, M K Olsen, J O Hui, D J Staples, T K Sawyer, R L Heinrikson, C S Tomich.   

Abstract

The aspartyl protease of human immunodeficiency virus 1 (HIV-1) has been expressed in Escherichia coli at high levels, resulting in the formation of inclusion bodies which contain denatured insoluble aggregates of the protease. After solubilization of these inclusion bodies in guanidinium chloride, the protease was purified to apparent homogeneity by a single-step reverse-phase HPLC procedure. The purified, but inactive, protein was denatured in 8 M urea and refolded to produce the active protease. Enzyme activity was demonstrated against the substrate H-Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-OH, modeled after the cleavage region between residues 128 and 135 in the HIV gag polyprotein. With this substrate, a Vmax of 1.3 +/- 0.2 mumol/(min.mg) and KM of 2.0 +/- 0.3 mM were determined at pH 5.5. Pepstatin (Iva-Val-Val-Sta-Ala-Sta-OH) and substrate analogues with the Tyr-Pro residues substituted by Sta, by Phe psi [CH2N]Pro, and by Leu psi [CH(OH)CH2]Val inhibited the protease with KI values of 360 nM, 3690 nM, 3520 nM, and less than 10 nM, respectively. All were competitive inhibitors, and the tightest binding compound provided an active site titrant for the quantitative determination of enzymatically active HIV-1 protease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182116     DOI: 10.1021/bi00453a036

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer.

Authors:  Y S Cheng; F H Yin; S Foundling; D Blomstrom; C A Kettner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Fengling Liu; Xianfeng Chen; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

4.  Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase.

Authors:  K Partin; H G Kräusslich; L Ehrlich; E Wimmer; C Carter
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

5.  Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease.

Authors:  Sook-Kyung Lee; Marc Potempa; Madhavi Kolli; Ayşegül Özen; Celia A Schiffer; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

6.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Development of activity assays for high-volume evaluation of human immunodeficiency virus (HIV) protease inhibitors in rat serum: results with ditekiren.

Authors:  K F Wilkinson; B D Rush; S K Sharma; D B Evans; M J Ruwart; J M Friis; M J Bohanon; P K Tomich
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

8.  Sensitive, hydrosoluble, macromolecular fluorogenic substrates for human immunodeficiency virus 1 proteinase.

Authors:  F Anjuère; M Monsigny; Y Lelièvre; R Mayer
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

9.  Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Protein Sci       Date:  1992-10       Impact factor: 6.725

10.  Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease.

Authors:  A G Tomasselli; J L Sarcich; L J Barrett; I M Reardon; W J Howe; D B Evans; S K Sharma; R L Heinrikson
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.